Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) had Return on Equity of -24.93% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-2.17M |
|
-- |
|
-- |
|
$2.24M |
|
$-2.24M |
|
$0.08M |
|
$-2.17M |
|
$-2.17M |
|
$-2.17M |
|
$-2.17M |
|
$-2.17M |
|
$-2.17M |
|
$-2.24M |
|
$-2.24M |
|
8.00M |
|
8.00M |
|
$-0.24 |
|
$-0.24 |
|
| Balance Sheet Financials | |
$9.96M |
|
$0.16M |
|
$0.28M |
|
$10.24M |
|
$1.55M |
|
-- |
|
-- |
|
$1.55M |
|
$8.69M |
|
$8.69M |
|
$8.69M |
|
7.25M |
|
| Cash Flow Statement Financials | |
$-3.74M |
|
$2.11M |
|
$0.07M |
|
$7.56M |
|
$6.00M |
|
$-1.56M |
|
$0.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.75M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-24.93% |
-24.93% |
|
-21.15% |
|
-24.93% |
|
$1.20 |
|
$-0.47 |
|
$-0.47 |
|